Tech Company Financing Transactions

Ablative Solutions Funding Round

Ablative Solutions secured a $77 million Series D investment round on 1/4/2019. Investors included BioStar Ventures, Gilde Healthcare Partners and Michigan Accelerator Fund.

Transaction Overview

Company Name
Ablative Solutions
Announced On
1/4/2019
Transaction Type
Venture Equity
Amount
$77,000,000
Round
Series D
Investors

BioStar Ventures (Lead Investor) (Michael Fulton)

Gilde Healthcare Partners (Lead Investor) (Geoff Pardo)

Michigan Accelerator Fund

Novus Biotechnology

Proceeds Purpose
Funds from the round will be used to complete clinical trials in support of U.S. and European regulatory submissions for the company's minimally invasive renal denervation technology designed to help reduce blood pressure for people with uncontrolled hypertension, while taking antihypertensive medication.

Company Information

Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
6203 San Ignacio Ave. 110
San Jose, CA 95119
USA
Phone
(650) 688-9743
Website
www.ablativesolutions.com
Email Address
[email protected]
Overview
Ablative Solutions is a medical device firm thatoffers an alternative to surgical renal denervation for treating hypertension.
Profile
Ablative Solutions LinkedIn Company Profile
Social Media
Ablative Solutions Company Twitter Account
Company News
Ablative Solutions News
Facebook
Ablative Solutions on Facebook
YouTube
Ablative Solutions on YouTube

Management Team

Title
Name
Email & Social
Chairman
David Fischell
  David Fischell LinkedIn Profile  David Fischell Twitter Account  David Fischell News  David Fischell on Facebook
Chief Executive Officer
Kate Rumrill
  Kate Rumrill LinkedIn Profile  Kate Rumrill Twitter Account  Kate Rumrill News  Kate Rumrill on Facebook
Chief Medical Officer
Timothy Fischell
  Timothy Fischell LinkedIn Profile  Timothy Fischell Twitter Account  Timothy Fischell News  Timothy Fischell on Facebook
VP - Bus. Development
Thomas Moore
  Thomas Moore LinkedIn Profile  Thomas Moore Twitter Account  Thomas Moore News  Thomas Moore on Facebook
VP - Finance
Lisa Mastromattei
  Lisa Mastromattei LinkedIn Profile  Lisa Mastromattei Twitter Account  Lisa Mastromattei News  Lisa Mastromattei on Facebook
VP - R & D
Darrin Kent
  Darrin Kent LinkedIn Profile  Darrin Kent Twitter Account  Darrin Kent News  Darrin Kent on Facebook
VP - Regulatory Affairs
Sonia Charrier
  Sonia Charrier LinkedIn Profile  Sonia Charrier Twitter Account  Sonia Charrier News  Sonia Charrier on Facebook
VP - Regulatory Affairs
Nicole Haratani
  Nicole Haratani LinkedIn Profile  Nicole Haratani Twitter Account  Nicole Haratani News  Nicole Haratani on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/4/2019: Cabaletta Bio venture capital transaction
Next: 1/4/2019: CarDekho venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.